ACELYRIN shares are trading higher after the company announced that its Phase 3 trial of Izokibep in hidradenitis suppurativa met the primary endpoint of HiSCR75 at 12 weeks.
Portfolio Pulse from Benzinga Newsdesk
ACELYRIN shares are trading higher after the company announced that its Phase 3 trial of Izokibep in hidradenitis suppurativa met the primary endpoint of HiSCR75 at 12 weeks.
August 13, 2024 | 8:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ACELYRIN shares are trading higher after the company announced successful Phase 3 trial results for Izokibep in treating hidradenitis suppurativa.
The successful Phase 3 trial results for Izokibep are a significant milestone for ACELYRIN, likely boosting investor confidence and driving the stock price higher in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100